文献速递肝病消化道肿瘤与早癌

高级执业提供者对肝硬化患者的照护质量与结局

The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers.
PubMed 文献 · Hepatology · 2019-06-21

基于美国商业理赔数据库389,257例肝硬化成人的回顾性分析显示,接受高级执业提供者(APP)照护的患者肝细胞癌筛查、食管静脉曲张筛查及肝性脑病出院后利福昔明使用率更高,30天再入院风险更低,死亡风险更低;APP与消化科/肝病科医师共同接诊时质量指标表现最佳。

要点

  • APP参与照护与更高的肝细胞癌筛查(OR 1.23)、静脉曲张筛查(OR 1.20)和肝性脑病后利福昔明使用(OR 2.09)相关。
  • APP照护与30天再入院风险降低相关(OR 0.68),死亡风险亦更低(调整HR 0.57)。
  • 消化科/肝病科医师与APP共同接诊时质量指标最佳,30天再入院低于无APP的专科会诊(OR 0.91)。

核心结论

  • APP参与照护,尤其是与消化科/肝病科医师协作时,与肝硬化患者照护质量和结局改善相关。

研究设计与样本

  • 回顾性分析美国全国代表性商业理赔数据库(Optum),纳入389,257例独特肝硬化成人。

主要发现

  • 与无APP照护者相比,有APP照护者肝细胞癌筛查率更高(调整OR 1.23,95%CI 1.19–1.27)。
  • 有APP照护者食管静脉曲张筛查率更高(OR 1.20,95%CI 1.13–1.27)。
  • 有APP照护者肝性脑病出院后利福昔明使用率更高(OR 2.09,95%CI 1.80–2.43)。
  • 有APP照护者30天再入院风险更低(OR 0.68,95%CI 0.66–0.70)。
  • 消化科/肝病科与APP共同接诊者30天再入院低于无APP的专科会诊(OR 0.91,95%CI 0.87–0.95)。

关键数值与推荐

  • 有APP照护者肝细胞癌筛查调整OR 1.23(95%CI 1.19–1.27),高于无APP照护者。
  • 有APP照护者静脉曲张筛查OR 1.20(95%CI 1.13–1.27),高于无APP照护者。
  • 有APP照护者肝性脑病出院后利福昔明使用OR 2.09(95%CI 1.80–2.43),高于无APP照护者。
  • 有APP照护者30天再入院OR 0.68(95%CI 0.66–0.70),低于无APP照护者。
  • 有APP照护者死亡调整HR 0.57(95%CI 0.55–0.60),低于无APP照护者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cirrhosis is morbid and increasingly prevalent, yet the U.S. health care system lacks enough physicians and specialists to adequately manage patients with cirrhosis. Although advanced practice providers (APPs) can expand access to cirrhosis-related care, their impact on the quality of care remains unknown. We sought to determine the effect on care quality and outcomes for patients managed by APPs using a retrospective analysis of a nationally representative American commercial claims database (Optum), which included 389,257 unique adults with cirrhosis. We evaluated a complication of process measures (i.e., rates of hepatocellular carcinoma [HCC] screening, endoscopic varices screening, and use of rifaximin after hospitalization for hepatic encephalopathy) and outcomes (30-day readmissions and survival). Compared with patients without APP care, patients with APP care had higher rates of HCC screening (adjusted odds ratio [OR] 1.23, 95% confidence interval 1.19, 1.27), varices screening (OR 1.20 [1.13, 1.27]), use of rifaximin after a discharge for hepatic encephalopathy (OR 2.09 [1.80, 2.43]), and reduced risk of 30-day readmission (OR 0.68 [0.66, 0.70]). Gastroenterology/hepatology consultation was also associated with improved quality metric performance compared with primary care; however, shared visits between gastroenterologists/hepatologists and APPs were associated with the best performance and lower 30-day readmissions compared with subspecialty consultation without an APP (OR 0.91 [0.87, 0.95]. Multivariate analysis adjusting for comorbidities, liver disease severity, and other factors including gastroenterology/hepatology consultation showed that patients seen by APPs were more likely to receive consistent HCC and varices screening over time, less likely to experience 30-day readmissions, and had lower mortality (adjusted hazard ratio 0.57, 95% confidence interval 0.55, 0.60). Conclusion: APPs, particularly when working with gastroenterologists/hepatologists, are associated with improved quality of care and outcomes for patients with cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Tapper EB, Hao S, Lin M, et al. The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. Hepatology. 2019. PMID: 31063262. doi:10.1002/hep.30695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。